Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Listed as NCT01396421, this PHASE3 trial focuses on Acute Schizophrenia and remains completed. Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., it has been updated 7 times since 2011, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arad, Romania , Austin, United States , Belgrade, Serbia , Bradenton, United States , Bucharest, Romania , Burlington, Canada , Charleston, United States , Chatham, Canada , Chernihiv, Ukraine , Choroszcz, Poland and 39 more locations